Parnell Pharmaceuticals Holdings EPS - Earnings per Share 2014-2018 | PARNF
Parnell Pharmaceuticals Holdings eps - earnings per share from 2014 to 2018. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Parnell Pharmaceuticals Holdings Annual EPS |
| 2021 |
$-0.04 |
| 2020 |
$-0.56 |
| 2019 |
$-0.28 |
| 2018 |
$0.01 |
| 2017 |
$0.00 |
| 2016 |
$-1.02 |
| 2015 |
$-0.78 |
| 2014 |
$-1.19 |
| 2014 |
$0.00 |
| 2013 |
$-0.47 |
| 2013 |
$0.00 |
| 2012 |
$0.00 |
| Parnell Pharmaceuticals Holdings Quarterly EPS |
| 2018-06-30 |
$0.00 |
| 2018-03-31 |
$0.00 |
| 2017-12-31 |
$0.00 |
| 2016-12-31 |
$-0.12 |
| 2016-09-30 |
$-0.27 |
| 2015-12-31 |
$-0.45 |
| 2015-09-30 |
$-0.13 |
| 2015-06-30 |
$-0.19 |
| 2015-03-31 |
$0.00 |
| 2014-12-31 |
$0.00 |
| 2014-09-30 |
$-0.10 |
| 2014-06-30 |
$0.00 |
| 2014-03-31 |
$-0.61 |
| 2013-06-30 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.000B |
$0.000B |
|
Parnell Pharmaceuticals Holdings Ltd. is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing animal health solutions. It manufactures and markets cattle reproduction, cattle mastitis, anesthetics, laminitis treatment, and orthopedic treatment products. The Company operates in four segments: Companion Animal, Production Animal-Unites States, and Production Animal-rest of the world and Manufacturing Operations. ZYDAX (R), GLYDE (R) and TERGIVE (R) are Parnell's premium osteoarthritis product suite. Parnell Pharmaceuticals Holdings Ltd. is headquartered in Alexandria, Australia.
|
